Stoke Therapeutics
STOK
64 hedge funds and large institutions have $948M invested in Stoke Therapeutics in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
180% more capital invested
Capital invested by funds: $339M → $948M (+$609M)
145% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 11
53.6% more ownership
Funds ownership: 48.7% → 102.3% (+54%)
21% more funds holding
Funds holding: 53 → 64 (+11)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.56M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.97M |
| 3 |
RI
RTW Investments
New York
|
+$4.75M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$4.42M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$9.44M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$2.5M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.26M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$1.24M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$647K |
STOK Hedge Fund Activity: Q4 2019 in Review
64 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q4 2019, worth a combined $948M — up 180% from $339M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new STOK positions and 4 closed out — a net gain of 11 holders — while 27 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $7.56M. The largest seller was Millennium Management, cutting an estimated $9.44M.
- 64 institutional investors held Stoke Therapeutics (STOK) as of Q4 2019, up from 53 in Q3 2019.
- Funds reported $948M of Stoke Therapeutics stock for Q4 2019, up 180% quarter-over-quarter.
- 15 funds opened new Stoke Therapeutics positions in Q4 2019 and 4 closed out, a net change of +11 holders.
- The largest Stoke Therapeutics buyer in Q4 2019 was BlackRock, an estimated $7.56M added.
- The largest Stoke Therapeutics seller in Q4 2019 was Millennium Management, an estimated $9.44M sold.
Based on aggregated 13F filings for Q4 2019.